Haberland syndrome

Haberland Syndrome: A Comprehensive Review

Introduction

Haberland syndrome, also known as encephalocraniocutaneous lipomatosis (ECCL) or Fishman syndrome, is an extraordinarily rare congenital neurocutaneous disorder first described by Catherine Haberland and Maurice Perou in 1970. This sporadic condition affects approximately 60-70 individuals worldwide since its initial description, making it one of the rarest neurocutaneous syndromes known to medicine. The syndrome represents a unique form of ectomesodermal dysgenesis characterized by a classic triad of unilateral cutaneous lipomatous lesions, ipsilateral central nervous system malformations, and ocular abnormalities.^{[1][2][3][4][5][6]}

The disorder exemplifies the complexity of neurocutaneous syndromes, with manifestations that can vary dramatically between affected individuals while maintaining consistent patterns of unilateral involvement. According to the National Institutes of Health Genetic and Rare Diseases Information Center (GARD) and Orphanet, ECCL is classified as a rare neoplastic syndrome characterized by unilateral lipomas of the cranium, face, and neck with ipsilateral cerebral malformations.^[7][8]

Etiology and Pathophysiology

Genetic Basis

Recent advances in molecular genetics have revealed that Haberland syndrome is a mosaic RASopathy caused by somatic mutations occurring during early embryonic development. The condition results from postzygotic mutations in genes within the RAS/MAPK signaling pathway, including FGFR1, KRAS, NRAS, and less commonly HRAS. These mutations lead to dysregulation of cellular proliferation, differentiation, and apoptosis, manifesting as the characteristic lipomatous and neural malformations.^[9][10][7]

The pathophysiology involves somatic mosaicism, where only certain cell populations carry the pathogenic mutation, explaining the characteristic unilateral distribution of lesions. This mosaicism occurs due to lethal autosomal dominant mutations that can only survive in a mosaic state, as constitutional presence of these mutations would be incompatible with life. The timing of the mutation during embryogenesis determines the extent and severity of the phenotype, with earlier mutations causing more widespread involvement.^[11][4][9]

Developmental Mechanism

The syndrome results from disrupted neural crest cell migration and anterior neural tube development. The affected neural crest cells contribute to the formation of craniofacial structures, peripheral nervous system, and meninges, explaining the characteristic distribution of lesions primarily affecting the head and neck region. The dysregulated RAS/MAPK signaling leads to abnormal lipomatous tissue proliferation and associated structural brain malformations on the ipsilateral side.^[4][9]

Clinical Presentation

Diagnostic Triad

The classic triad of Haberland syndrome encompasses:^[3][4]

1. Cutaneous manifestations: Unilateral lipomatous hamartomas and alopecia
2. Central nervous system abnormalities: Intracranial lipomas and structural malformations
3. Ocular abnormalities: Choristomas and associated eye defects

Dermatological Features

The hallmark cutaneous feature is nevus psiloliparus, a well-demarcated, hairless fatty tissue nevus of the scalp present in approximately 80% of patients. This pathognomonic lesion consists of subcutaneous lipomatous tissue beneath smooth, alopecic skin typically located in the frontotemporal or parietal regions. Additional dermatological manifestations include:^{[12][1][3][7]}

• Patchy or streaky non-scarring alopecia without fatty nevus
• Subcutaneous lipomas in frontotemporal regions
• Focal skin aplasia or hypoplasia on the scalp
• Small nodular skin tags on eyelids or between the outer canthus and tragus
• Linear hyperpigmentation following Blaschko’s lines
• Periocular skin abnormalities^[3][7]

Neurological Manifestations

Central nervous system involvement occurs in approximately 61% of patients and represents the most clinically significant aspect of the syndrome. Key neurological features include:^[7]

Structural Abnormalities:

• Intracranial lipomas, most commonly located at the cerebellopontine angle
• Intraspinal lipomas, typically cervicothoracic
• Unilateral cerebral hemispheric atrophy
• Porencephalic cysts and arachnoid cysts
• Asymmetrically dilated ventricles or hydrocephalus
• Leptomeningeal angiomatosis
• Polymicrogyria affecting temporal, parietal, or occipital lobes^[3][7]

Clinical Neurological Presentations:

• Seizures (present in 80-90% of cases), typically generalized tonic-clonic
• Intellectual disability ranging from mild to severe (though one-third have normal intelligence)
• Contralateral hemiplegia or spasticity
• Global developmental delay
• Psychomotor retardation^[2][12][3]

Ocular Abnormalities

Ocular involvement occurs in approximately 80% of patients, with choristomas (epibulbar dermoids or lipodermoids) being the most characteristic finding. Other ophthalmic manifestations include:^[1][7]

• Corneal and anterior chamber anomalies
• Eyelid colobomas
• Globe calcification
• Microphthalmia
• Sclerocornea
• Iris hypoplasia
• Hypertrophic conjunctivae
• Absent macular reflex^[7][3]

Additional Systemic Manifestations

While primarily affecting the head and neck, Haberland syndrome can involve other organ systems:

Skeletal System:

• Jaw tumors (odontomas, osteomas, ossifying fibromas)
• Multiple bone cysts
• Facial asymmetry and cranial deformities^[3]

Cardiovascular System:

• Cardiac lipomatosis (rare)
• Coarctation of aorta
• Septal defects^[12][3]

Genitourinary System:

• Cryptorchidism
• Hydronephrosis
• Renal anomalies^[7]

Diagnosis

Clinical Diagnostic Criteria

The diagnosis of Haberland syndrome is established using criteria originally proposed by Hunter in 2006 and subsequently modified by Moog in 2009. The diagnostic framework employs major and minor criteria across four organ systems:^[4][3]

Skin System Major Criteria:

1. Proven nevus psiloliparus
2. Possible nevus psiloliparus plus >1 minor criteria
3. 2 minor criteria^[3]

Central Nervous System Major Criteria:

1. Intracranial lipoma
2. Intraspinal lipoma
3. Two or more minor criteria^[3]

Ocular Major Criteria:

1. Choristoma with or without associated anomalies^[3]

Imaging Studies

Magnetic Resonance Imaging (MRI) is the gold standard for evaluating CNS involvement and should include:^[13]

• Brain MRI to assess for intracranial lipomas, hemispheric atrophy, and cystic lesions
• Spinal MRI to evaluate for intraspinal lipomatosis
• Fat-suppressed sequences to better characterize lipomatous lesions
• Vascular imaging to assess for angiomatous malformations

Computed Tomography (CT) may reveal:

• Intracranial calcifications
• Bony abnormalities
• Hydrocephalus
• Asymmetric ventricular enlargement^[2][12]

Histopathological Examination

Biopsy of cutaneous lesions demonstrates:

• Mature adipose tissue
• Hamartomatous elements
• Focal dermal fibrosis with subcutaneous fat extension into the reticular dermis
• Absence of sebaceous glands in alopecic areas^[3]

Genetic Testing

While not required for diagnosis, molecular genetic testing can identify mosaic mutations in FGFR1, KRAS, NRAS, or HRAS genes. Testing should be performed on affected tissue (typically skin) rather than blood, as mosaicism may not be detectable in peripheral blood samples.^[10][9]

Differential Diagnosis

Haberland syndrome must be differentiated from other neurocutaneous disorders:^[3]

Proteus Syndrome:

• Progressive, bilateral involvement
• Cerebriform nevi on soles
• Normal brain development in most cases

Sebaceous Nevus Syndrome (Linear Nevus Sebaceous Syndrome):

• Midline facial lesions
• Sebaceous nevi rather than lipomatous lesions

Oculocerebrocutaneous (OCC) Syndrome:

• Absence of scalp alopecia and facial lipomas
• Predominant orbital cysts

Goldenhar Syndrome:

• Hemifacial microsomia
• Vertebral anomalies
• Absence of lipomatous lesions

Management and Treatment

Multidisciplinary Approach

Currently, no curative treatment exists for Haberland syndrome. Management requires a multidisciplinary team approach coordinated through specialized centers, as recommended by the National Institute of Neurological Disorders and Stroke (NINDS) and European Reference Networks for rare diseases.^[14][15]

Neurological Management

Seizure Control:

• Anti-epileptic drugs (AEDs) tailored to seizure type and patient age
• Regular neurological monitoring and EEG surveillance
• Consideration of epilepsy surgery in refractory cases
• Ketogenic diet in selected patients with medication-resistant epilepsy^[2][3]

Neurodevelopmental Support:

• Early intervention programs
• Physical and occupational therapy for motor dysfunction
• Speech and language therapy
• Special education services as needed^[3]

Neurosurgical Considerations:

• Surgical management of symptomatic intracranial lipomas (rare)
• Treatment of hydrocephalus with shunting if indicated
• Management of increased intracranial pressure^[3]

Dermatological Management

Cosmetic Correction:

• Surgical excision of cutaneous lipomas for cosmetic improvement
• Hair transplantation for alopecic areas
• Laser therapy for pigmentary abnormalities
• Management of skin tags^[14][1]

Ophthalmological Management

Ocular Interventions:

• Surgical excision of choristomas if vision-threatening
• Lamellar keratoplasty for corneal opacities
• Management of refractive errors
• Regular ophthalmological surveillance^[16]

Anesthetic Considerations

Patients with Haberland syndrome present unique anesthetic challenges, as detailed in case reports from specialized centers:^[2]

Airway Management:

• Difficult mask ventilation due to facial asymmetry
• Potential difficult intubation secondary to mandibular abnormalities
• Preparation for emergency surgical airway
• Fiberoptic bronchoscopy may be required

Perioperative Considerations:

• Risk of perioperative seizures
• Cardiac evaluation for associated anomalies
• Positioning challenges due to skeletal abnormalities
• Postoperative monitoring in intensive care settings

Cancer Surveillance

Patients with Haberland syndrome have an increased risk of developing low-grade gliomas, particularly pilocytic astrocytomas. Regular neuroimaging surveillance is recommended:^[13][7]

• Baseline brain MRI with contrast
• Annual or biannual follow-up imaging
• Prompt evaluation of new neurological symptoms
• Multidisciplinary oncological consultation when indicated

Prognosis and Outcomes

Neurological Outcomes

The prognosis of Haberland syndrome varies significantly based on the extent of CNS involvement:^[7][3]

Cognitive Development:

• Approximately one-third of patients have normal intelligence
• One-third experience mild developmental delay or intellectual disability
• One-third have severe developmental delay or intellectual disability

Seizure Prognosis:

• Seizures typically begin in early childhood
• May be refractory to medical management
• Can contribute to developmental regression if poorly controlled

Motor Function:

• Contralateral weakness or spasticity common
• Severity correlates with extent of hemispheric involvement
• Early intervention can improve functional outcomes

Life Expectancy

Most patients with Haberland syndrome have a normal life expectancy if serious complications are avoided. However, factors that may impact prognosis include:^[3]

• Severity of CNS malformations
• Degree of intellectual disability
• Presence of refractory epilepsy
• Development of secondary complications (hydrocephalus, infections)
• Risk of malignant transformation (rare)

Quality of Life

With appropriate multidisciplinary management, many patients can achieve good quality of life. Factors influencing outcomes include:^[3]

• Early recognition and intervention
• Access to specialized care
• Family support and resources
• Educational accommodations
• Cosmetic interventions when desired

Epidemiology and Genetics

Prevalence and Demographics

Haberland syndrome affects fewer than 100 individuals worldwide since its description in 1970. The condition shows:^[4][3]

• No gender predilection
• No racial or geographic clustering
• Sporadic occurrence (no familial cases reported)
• Estimated prevalence: <1 in 1,000,000 individuals

Inheritance Pattern

The syndrome is not inherited in the traditional sense, as it results from de novo somatic mutations occurring during embryogenesis. Key genetic features include:^[9][4]

• Sporadic occurrence with no family history
• No increased recurrence risk for siblings
• Minimal gonadal mosaicism risk (theoretical)
• No genetic testing required for family members

Genetic Counseling

Families should receive comprehensive genetic counseling addressing:^[4]

• Nature of somatic mosaicism
• Extremely low recurrence risk
• Reproductive implications (minimal risk to offspring)
• Availability of prenatal diagnosis (generally not indicated)
• Psychosocial support and family planning considerations

Research Directions and Future Perspectives

Molecular Research

Current research focuses on:^[10][9]

• Characterizing the full spectrum of genetic mutations
• Understanding genotype-phenotype correlations
• Investigating cellular mechanisms of RAS/MAPK dysregulation
• Developing targeted therapeutic approaches

Therapeutic Development

Potential future treatments being investigated include:

• MEK inhibitors for RAS pathway modulation
• mTOR inhibitors for seizure control and tumor prevention
• Gene therapy approaches for mosaic conditions
• Regenerative medicine for cosmetic reconstruction

Clinical Registries

International collaboration through organizations like Orphanet and the European Reference Networks aims to:

• Establish natural history studies
• Develop treatment guidelines
• Facilitate clinical trials
• Improve diagnostic capabilities

Conclusion

Haberland syndrome represents a fascinating example of how somatic mosaicism can create complex, multisystem disorders affecting primarily the neurocutaneous systems. While extremely rare, the condition provides important insights into embryonic development, neural crest cell biology, and RAS pathway signaling. The unilateral nature of the lesions and the variable expressivity underscore the critical importance of timing during embryogenesis and the mosaic distribution of pathogenic mutations.

Early recognition of the characteristic triad—nevus psiloliparus, intracranial lipomas, and ocular choristomas—enables appropriate multidisciplinary management and family counseling. While no curative treatments exist, symptomatic management can significantly improve quality of life for affected individuals. The identification of underlying RAS pathway mutations opens potential avenues for targeted therapies, though the mosaic nature of the condition presents unique therapeutic challenges.

As our understanding of mosaic disorders continues to evolve, Haberland syndrome serves as an important paradigm for the broader category of neurocutaneous syndromes caused by somatic mutations. Continued research into the molecular mechanisms, natural history, and therapeutic interventions will be essential for improving outcomes for the small but important population of individuals affected by this remarkable syndrome.

Healthcare providers should maintain awareness of this condition when evaluating patients with unilateral neurocutaneous anomalies, particularly those presenting with the pathognomonic nevus psiloliparus and associated neurological manifestations. Early diagnosis facilitates appropriate medical management, genetic counseling, and access to specialized care resources essential for optimizing long-term outcomes.

References

1. https://oftalmoloji.org/articles/encephalocraniocutaneous-lipomatosis-associated-with-orbital-cyst-a-variant-or-new-entity/doi/tjo.galenos.2020.84584   
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6644190/    
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC5723105/                     
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11781344/       
5. 1.pdf
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9868236/
7. https://www.malacards.org/card/encephalocraniocutaneous_lipomatosis          
8. https://rarediseases.info.nih.gov/diseases/2108/encephalocraniocutaneous-lipomatosis
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC7081367/     
10. https://www.ncbi.nlm.nih.gov/books/NBK576966/  
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC5134170/
12. https://www.elsevier.es/en-revista-neurologia-english-edition–495-articulo-haberland-syndrome-clinical-neuroimaging-findings-S2173580818300762   
13. https://radiopaedia.org/articles/encephalocraniocutaneous-lipomatosis 
14. https://www.fortunejournals.com/articles/encephalocraniocutaneous-lipomatosis-haberland-syndrome-with-atrial-tachycardia-in-a-neonate-a-rare-case-report.html 
15. https://www.ninds.nih.gov/health-information/disorders/mitochondrial-disorders
16. https://www.cureus.com/articles/91437-encephalocraniocutaneous-lipomatosis-a-case-report-and-literature-review
17. https://www.sciencedirect.com/science/article/pii/S1930043320300492
18. https://en.wikipedia.org/wiki/Encephalocraniocutaneous_lipomatosis
19. https://www.eurorad.org/case/19157
20. https://emedicine.medscape.com/article/1117060-overview
21. https://medlineplus.gov/genetics/condition/encephalocraniocutaneous-lipomatosis/
22. https://www.sciencedirect.com/science/article/abs/pii/S1071909124000524
23. https://www.orpha.net/en/disease/detail/2396
24. https://en.wikipedia.org/wiki/Mosaic_(genetics)
25. https://emedicine.medscape.com/article/1117060-clinical
26. https://www.sciencedirect.com/science/article/abs/pii/B9780444627025000196
27. http://iamg.in/genetic_clinics/full_text1c4b.html?id=431
28. https://www.genetics.edu.au/SitePages/Mosaicism.aspx
29. https://discovery.ucl.ac.uk/10073400/7/Kinsler_Mosaic abnormalities of the skin-review and guidelines from the European Reference Network for rare skin diseases (ERN-Skin)_AAM.pdf
30. https://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.62356
31. https://www.orpha.net
32. https://pmc.ncbi.nlm.nih.gov/articles/PMC7744584/
33. https://doaj.org/article/4d9663d5bc03443cb705ccde5b6f0c94
34. https://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.64202
35. https://www.nature.com/articles/s41431-019-0508-0
36. https://www.orpha.net/en/disease
37. https://kleijhsbr.researchcommons.org/journal/vol9/iss3/17/
38. https://id-genes.orphanet.app
39. https://www.orpha.net/en/disease/detail/117
40. https://rarediseases.org/mondo-disease/encephalocraniocutaneous-lipomatosis/
41. https://rarediseases.org/organizations/orphanet/
42. https://health.ec.europa.eu/document/download/b5e6c097-a414-4e39-9654-0f61fe153e27_en
43. https://doaj.org/article/4f7d562b318b408fabed9e4b81332763